NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Cytosorbents Corporation CTSO
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$37.1M
▲ 4.1% vs FY2024
EPS · FY25
$-0.13
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-96.4%
Net margin · FY25
-22.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 37.1M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 22 cents on every revenue dollar this year.
Per share
USD -0.13
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-96.4%
Return on equity, FY2025
ROE
Operating margin-39.8%
Net margin-22.1%
Return on assets-17.9%
Each USD of equity lost 96 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−2.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.2%
−2.0%
+22.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+45.3%
Change, 10 years+147.3%
The share count grew 45% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 44.2M
total assets, end of FY2025
Total assetsUSD 44.2M
EquityUSD 5.9M
CashUSD 6.2M
Gross debtUSD 16.7M
Net debtUSD 10.4M
Current ratio2.13×
Net debt stands at 176% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.13
−0.38
−0.65
−0.75
−0.57
−0.20
−0.60
−0.56
−0.32
−0.46
−0.38
−1.29
−0.75
−0.03
−0.05
−0.05
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−96.4
−119.8
−99.4
−67.0
−34.6
−19.0
−189.3
−126.6
−145.9
−210.4
−112.9
·
·
·
·
·
·
·
·
Shares out B
0.06
0.05
0.05
0.04
0.04
0.04
0.03
0.03
0.03
0.03
0.03
0.02
0.01
0.21
0.18
0.12
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
62 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed